Since April 2019
Patent Attorney at df-mp
Claudia Eisner
(nee. Gonnermann)
Patent Attorney
Dr. rer. biol. hum., Pharmacist
Dr. Claudia Eisner (nee. Gonnermann) is a member of the df-mp‘s Pharmaceuticals, Biotechnology and Chemistry Division. Dr. Claudia Eisner has comprehensive experience as Inhouse Senior Patent Counsel in the biopharmaceutical industry and long-term expertise in in the Life Science department of international patent law firms. She is authorized to represent clients before the European Patent Office (EPO), the German Patent and Trademark Office (GPTO), the German Federal Patent Court (GFPC), the German Federal Supreme Court (FSC; in appeals from the GFPC) as well as the European Union Intellectual Property Office (EUIPO). She has been active in intellectual property law since 2004 and joined df-mp in 2019.
+ 49 89 210 296 0
claudia.eisner@df-mp.com
Dr. Claudia Eisner (nee. Gonnermann) is a member of the df-mp‘s Pharmaceuticals, Biotechnology and Chemistry Division. Dr. Claudia Eisner has comprehensive experience as Inhouse Senior Patent Counsel in the biopharmaceutical industry and long-term expertise in in the Life Science department of international patent law firms. She is authorized to represent clients before the European Patent Office (EPO), the German Patent and Trademark Office (GPTO), the German Federal Patent Court (GFPC), the German Federal Supreme Court (FSC; in appeals from the GFPC) as well as the European Union Intellectual Property Office (EUIPO). She has been active in intellectual property law since 2004 and joined df-mp in 2019.
practice areas.
Dr. Claudia Eisner’s technical expertise covers inter alia the areas of pharmaceutical drugs and technology, molecular biology, biotechnology, immunology, neurosciences and medical devices. Her practice focuses on patent disputes, in particular opposition proceedings before the EPO, nullity proceedings before the GFPC, participation in patent infringement proceedings and provision of corresponding opinions. She also handles prosecution of patent applications before the EPO and GPTO as well as their coordination worlwide. Dr. Claudia Eisner has comprehensive experience in the field of employee invention remuneration.
admissions.
- German Patent Attorney
- European Patent Attorney
- European Trademark Attorney
- European Design Attorney
curriculum vitae.
2015-2019
Senior Patent Counsel in the patent department of the international biopharmaceutical company AbbVie Deutschland GmbH & Co. KG, Ludwigshafen .
2009-2015
Patent Attorney in the international law firm Bird & Bird, LLP, Munich, Germany
2007-2009
Patent Attorney at the law firm Weickmann & Weickmann, Munich, Germany
2004-2007
Patent attorney candidate at the law firm Weickmann & Weickmann, at the German Patent and Trademark Office and the German Federal Patent Court, Munich
2000-2004
Doctorate and scientific employee at the Ludwig-Maximilians-University, Psychiatric Clinic and Polyclinic of the University Munich, Germany, department Molecular and Clinic Neurobiology, Ph. D. thesis: "The interleukin-1 gene complex in schizophrenia"
1993-2000
First pharmaceutical state examination at the Eberhardt-Karls-University, Tübingen, Germany, second and third pharmaceutical state examination at the Ludwig-Maximilians-University, Munich, as well as License to practice as Pharmacist at the Government of Upper Bavaria, Munich, Germany
publications.
- Gonnermann C.,,Patentability of medical devices under German and European patent law“ (2009); https://www.jura.uni-augsburg.de/forschung/forschungsstellen/fmpr/downloads/01-Gonnermann.pdf
- Gonnermann C., Giegling I., Dahmen N., MüIIer J., Möller H.-J., Rujescu D., (2003) ,,An interleukin-1 receptor antagonist gene polymorphism may be associated with schizophrenia“, Pharmacopsychiatry, 36 – 92, Thieme-connect / Abstract; https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2003-825343
- Rujescu D., Hartmann A.M., Gonnermann C., Möller H.-J., Giegling I. (2003) “M129V variation in the prion protein may influence cognitive performance”, Molecular Psychiatry, 8 (11): 937 – 41; https://www.ncbi.nlm.nih.gov/pubmed/14593432; article in “Süddeutsche Zeitung” of 06.11.03, p. 12
- Rujescu D., Giegling I., Gietl A., Gonnermann C., Kirner A., Möller H.-J., Dahmen D. (2003) “Association study of a SNP coding for a M129V substitution in the prion protein in schizophrenia”, Schizophrenia research, 62 (3): 289 – 91; https://www.ncbi.nlm.nih.gov/pubmed/14593432
